Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer-associated fibroblast-secreted FGF2 faliciates gastric cancer cell proliferation by enhancing ribosome biogenesis

ABSTRACT: Cell co-culture experiments and bioinformatics analysis show that soluble FGF2 plays an important role in the cross-talking between CAF and tumor cells. This study aimed to explore the efffects of human recombinant FGF2 protein (20 ng/mL) on the transcriptome of GC cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249966 | GEO | 2024/03/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Cancer-associated fibroblast-secreted FGF2 faliciates gastric cancer cell proliferation by enhancing ribosome biogenesis

Project description:Cancer-associated fibroblast-secreted FGF2 faliciates gastric cancer cell proliferation by enhancing ribosome biogenesis

| PRJNA1051512 | ENA

Extracellular vesicles from fibroblasts stimulated by FGF2

Project description:We compared proteomic analysis of extracellular vesicles (EVs) secreted from human dermal fibroblasts, either control or stimulated by FGF2 and after immunoprecipitation with FGF2-coated beads to isolated FGF2-positive EVs.

2022-12-20 | PXD033141 | Pride

FGF2

Project description:Monodelphis domestica FGF2, Monodelphis domestica fibroblast growth factor 2 (FGF2), mRNA. [Source:RefSeq mRNA;Acc:NM_001033976], is expressed in 1 baseline experiment(s);

| ENSMODG00000018899 | ExpressionAtlas

Cancer-associated fibroblast-secreted IGFBP7 promotes gastric cancer by enhancing tumor associated macrophage infiltration via FGF2/FGFR1/PI3K/AKT axis.

Project description:We previously reported that IGFBP7 plays a role in maintaining mRNA stability of oncogenic lncRNA UBE2CP3 by RNA-RNA interaction in gastric cancer (GC). Clinical cohort studies had implied an oncogenic role of IGFBP7 in GC. However, the molecular mechanism of IGFBP7 in GC progression remains unknown. In this study, clinical analysis based on two independent cohorts showed that IGFBP7 was positively associated with poor prognosis and macrophage infiltration in GC. Loss-of-function studies confirmed the oncogenic properties of IGFBP7 in regulating GC cell proliferation and invasion. Mechanismly, IGFBP7 was highly expressed in cancer-associated fibroblasts (CAF) and mesenchymal cells, and was induced by epithelial-to-mesenchymal transition (EMT) signaling, since its expression was increased by TGF-beta treatment and reduced by overexpression of OVOL2 in GC. RNA sequencing, qRT-PCR, ELISA assay showed that IGFBP7 positively regulated FGF2 expression and secretion in GC. Transcriptome analysis revealed that FGFR1 was downregulated in M1 polarization but upregulated in M2 polarization. Exogenous recombinant IGFBP7 treatment in macrophages and GC cells further identified that IGFBP7 promotes tumor associated macrophage (TAM) polarization via FGF2/FGFR1/PI3K/AKT axis. Our finding here represented the first evidence that IGFBP7 promotes GC by enhancing TAM/M2 macrophage polarization through FGF2/FGFR1/PI3K/AKT axis.

| S-EPMC9867714 | biostudies-literature

The Ribosome Biogenesis-Cancer Connection.

Project description:Multifaceted relations link ribosome biogenesis to cancer. Ribosome biogenesis takes place in the nucleolus. Clarifying the mechanisms involved in this nucleolar function and its relationship with cell proliferation: 1) allowed the understanding of the reasons for the nucleolar changes in cancer cells and their exploitation in tumor pathology, 2) defined the importance of the inhibition of ribosome biogenesis in cancer chemotherapy and 3) focused the attention on alterations of ribosome biogenesis in the pathogenesis of cancer. This review summarizes the research milestones regarding these relevant relationships between ribosome biogenesis and cancer. The structure and function of the nucleolus will also be briefly described.

| S-EPMC6356843 | biostudies-literature

hES cell FGF2 re-stimulation experiments

Project description:This series includes hES cell samples starved and re-stimulated with FGF2. Controls were FGF2-starved but not re-stimulated. Two independent experiments were carried out (one sample plus control each). Keywords: Growth factor stimulation experiment

2006-10-03 | GSE5415 | GEO

FGF2 effects on the transcriptome of the human dermal fibroblasts

Project description:The current study was to determine the effects of Fibroblast Growth Factor 2 (FGF2) on the transcriptome of adult human dermal fibroblasts. Transcriptional profiles of adult human dermal fibroblasts grown in culture medium (with FGF2 or not) were compared. Comparison of the transcriptomes will allow to identify significantly differentially expressed genes exposure to FGF2, which in turn will allow for identification of the pathways affected by these factors in the human adult fibroblasts. Methods: Human dermal fibroblasts were FGF2 (10ng/ML) treatment for 48h hours. Then, the RNA was extracted for library construction Results: FGF2-responsive genes were significantly involved in ECM-receptor interaction, PI3K-Akt signaling and Hippo pathway.

2020-12-22 | GSE157071 | GEO

Fgf2

Project description:Rattus norvegicus Fgf2, fibroblast growth factor 2 [Source:RGD Symbol;Acc:2609], is differentially expressed in 13 experiment(s);

| ENSRNOG00000017392 | ExpressionAtlas

Fgf2

Project description:Rattus norvegicus Fgf2, fibroblast growth factor 2 [Source:RGD Symbol;Acc:2609], is expressed in 7 baseline experiment(s);

| ENSRNOG00000017392 | ExpressionAtlas

Effects of N-terminal truncated version of FGF2 on dissociated myelinating cultures

Project description:Analysis of the effects of different FGF2 variants (human FGFs-hFGF2, wild-type protein and N-terminal truncated FGF2-F2V2) on myelinating cultures generated from dissociated embryonic spinal cord after 24 hours treatment to give insights into the effects of the N-terminal region of FGF2 on FGF signalling and its implications in demyelinating diseases.

2019-12-09 | GSE65466 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data